Integrated BioPharma Announces Q4 2025 Financial Results

Integrated BioPharma, Inc. (OTCQX:INBP), based in Hillside, NJ, has reported its financial results for the quarter ended December 31, 2025. The company's revenue for this period was $11.3 million, marking a decrease from $12.6 million in the same quarter of the previous year, representing a decline of 10.3%. The operating loss totaled $0.9 million, a shift from the $0.2 million operating income reported for Q4 2024.

For the six months ended December 31, 2025, revenue reached $24.0 million, down from $26.2 million the previous year, an 8.4% decrease. The company recorded a net loss of $0.8 million for Q4 2025 compared to a net income of $0.1 million in Q4 2024. The diluted net loss per share stood at $(0.03), compared to $0.00 in Q4 2024.

Co-CEOs Riva Sheppard and Christina Kay noted that revenue from their two largest customers represented 89% of the total revenue for the period. The company continues to focus on its core business of manufacturing and distributing vitamins, nutritional supplements, and herbal products.